Abstract
Semaphorins (Semas), a family of evolutionarily conserved secreted and transmembrane proteins, were initially identified as axon guidance regulators and have since been implicated in the development of a number of other tissues. Sema signaling also regulates a variety of processes that are linked to cancer (i.e. metastasis, cell migration, cell growth). The mechanisms by which Sema signaling regulates axonogenesis and tumorigenesis are strikingly similar, making advances in either field applicable to the alternate discipline. Here, recent advances in understanding the roles of Semas in development and cancer, as well as the therapeutic potential for targeting this signaling pathway in human cancers, are reviewed.
Keywords: Semaphorin, Plexin, axon guidance, cancer, development
Current Drug Targets
Title: Semaphorins at the Interface of Development and Cancer
Volume: 10 Issue: 7
Author(s): E. Flannery and M. Duman-Scheel
Affiliation:
Keywords: Semaphorin, Plexin, axon guidance, cancer, development
Abstract: Semaphorins (Semas), a family of evolutionarily conserved secreted and transmembrane proteins, were initially identified as axon guidance regulators and have since been implicated in the development of a number of other tissues. Sema signaling also regulates a variety of processes that are linked to cancer (i.e. metastasis, cell migration, cell growth). The mechanisms by which Sema signaling regulates axonogenesis and tumorigenesis are strikingly similar, making advances in either field applicable to the alternate discipline. Here, recent advances in understanding the roles of Semas in development and cancer, as well as the therapeutic potential for targeting this signaling pathway in human cancers, are reviewed.
Export Options
About this article
Cite this article as:
Flannery E. and Duman-Scheel M., Semaphorins at the Interface of Development and Cancer, Current Drug Targets 2009; 10 (7) . https://dx.doi.org/10.2174/138945009788680383
DOI https://dx.doi.org/10.2174/138945009788680383 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Medicinal Chemistry of 5-HT5A Receptor Ligands: A Receptor Subtype with Unique Therapeutical Potential
Current Topics in Medicinal Chemistry Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer
Current Pharmaceutical Design Omega-3 Polyunsaturated Fatty Acids and Cancer
Anti-Cancer Agents in Medicinal Chemistry Vagotomy and Gastric Tumorigenesis
Current Neuropharmacology Co-formulation of P-glycoprotein Substrate and Inhibitor in Nanocarriers: An Emerging Strategy for Cancer Chemotherapy
Current Cancer Drug Targets Natural Antioxidants: Therapeutic Prospects for Cancer and Neurological Diseases
Mini-Reviews in Medicinal Chemistry Peptide Targeted Copper-64 Radiopharmaceuticals
Current Topics in Medicinal Chemistry Neuroprotection & Mechanism of Ethanol in Stroke and Traumatic Brain Injury Therapy: New Prospects for an Ancient Drug
Current Drug Targets Cell Cycle and Energy Metabolism in Tumor Cells: Strategies for Drug Therapy
Recent Patents on Anti-Cancer Drug Discovery Inhibitors of Cyclin Dependent Kinases: Useful Targets for Cancer Treatment
Current Cancer Drug Targets Tachykinins and their Receptors in Human Malignancies
Current Drug Targets Ellipticines as DNA-Targeted Chemotherapeutics
Current Medicinal Chemistry Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System
Current Pharmaceutical Design [177Lu]-DOTA0-Tyr3-Octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma
Current Radiopharmaceuticals Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy
Current Cancer Drug Targets A Systems Biology Road Map for the Discovery of Drugs Targeting Cancer Cell Metabolism
Current Pharmaceutical Design Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) Biocatalytic Synthesis of Terpene Esters and their Biological Activity in Human Glioma Cells
Current Pharmaceutical Biotechnology The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.
Current Molecular Medicine Cancer Nanotechnology - Prospects for Cancer Diagnostics and Therapy
Current Cancer Therapy Reviews